Key Highlights
- Geron (NASDAQ:GERN) reported third-quarter 2026 Rytelo net product Revenue of USD 60.1 million on November 4, 2026, up 5% from the second quarter, with nine-month revenue of USD 169.4 million.
- Net income was USD 1.4 million, or USD 0.00 per share, compared with a loss of USD 0.03 per share in the third quarter of 2025; the nine-month net loss was USD 19.0 million.
- Cash, equivalents, restricted cash and marketable securities were about USD 339.4 million at September 30, 2026, up from USD 326.9 million at June 30, 2026.
- Published market data lists the shares at USD 0.97, up 4.70% on 6.077 million shares; the snapshot date is not shown, so it cannot be tied to the November 4 release.
Rytelo Revenue Reaches USD 60.1 Million as Demand Grows
Geron (NASDAQ:GERN) is a commercial-stage biopharmaceutical company whose marketed product, Rytelo, treats certain patients with lower-risk myelodysplastic syndromes. In the company release dated November 4, 2026, third-quarter net product revenue was USD 60.1 million, up 5% from the second quarter, while the company said demand grew 10% sequentially. Ordering accounts rose about 8% to roughly 1,700. The company reiterated 2026 Rytelo net revenue guidance at the mid-to-high end of USD 220 million to USD 240 million, and it lowered total Operating Expense guidance to USD 220 million to USD 230 million from USD 230 million to USD 240 million. Management said existing cash plus expected U.S. Rytelo revenue is sufficient to fund projected operating needs for the foreseeable future, without giving a runway in months.
Break-Even Quarter, a Stopped Phase 3 Study and Europe
Third-quarter Net Income of USD 1.4 million rounds to USD 0.00 per share, an improvement from the USD 0.03 per-share loss a year earlier, though the nine-month net loss remains USD 19.0 million. Geron (NASDAQ:GERN) also discontinued the Phase 3 IMpactMF trial in myelofibrosis patients who no longer respond to JAK inhibitors after its Data Monitoring Committee judged the study unlikely to meet its overall survival endpoint; no new safety signals were reported. On the commercial side, a gated launch is under way in targeted European markets, with Germany expected by year-end and France in 2027. Nine-month Rytelo revenue of USD 169.4 million shows the launch is still scaling, though expansion abroad adds costs.
What the Penny Stock Label Means for Risk
At USD 0.97 on published market data, Geron (NASDAQ:GERN) is a penny stock, a label based on price alone (at or below USD 5). Thin trading is a general risk for such shares: a small number of trades can move the price, spreads can be wide and a quoted gain can reverse, and nothing here implies the move will continue. The 4.70% change and 6.077 million share Volume are screen figures that were not matched to an exchange record. A price below USD 1.00 can also raise Nasdaq bid-price questions, although no notice was found in this research.
Where Things Stand
Because the quarter showed commercial progress against a clinical setback. Geron (NASDAQ:GERN) reached break-even Earnings on USD 60.1 million of Rytelo sales and lowered its expense outlook, but it stopped the IMpactMF Phase 3 study after the monitoring committee flagged a low chance of success. Cash of about USD 339.4 million supports the company's stated view that it can fund operations for the foreseeable future. The 4.70% screen move is unverified, and the next checkpoints are fourth-quarter Rytelo sales, the German launch and expense discipline.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...